News
Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced the first patient has been dosed in the Phase 2 clinical trial ...
18h
News-Medical.Net on MSNSuppression of cdc42 activity could be a promising therapy for nephrotic syndromeA group led by the Department of Cell Biology at the Kidney Research Center, Niigata University revealed that elevated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results